

Duplicate of
paper # 23

AN 09/119,209

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants:	Lasky et al.	Examiner:	M. Pak
Application No.:	09/119,209	Group Art Unit:	1646
Filed:	July 20, 1998	Docket No.:	11669.98US01
Title:	LYMPHOCYTE HOMING RECEPTORS		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being transmitted by Express Mail to Commissioner for Patents, Washington, D.C. 20231, at TC1600 on March 10, 2003.

By: 
Name: Lynnda Kraft

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 14 2003

Dear Sir:

Responsive to the Office Action mailed October 22, 2001, the date for timely reply having been extended three months to expire on April 22, 2002, Applicants submit the following Amendment and Remarks. Entry of the Amendment and reconsideration of the claims and argument is respectfully requested.

TECH CENTER 1600/2900

In the Claims:

Please cancel claims 49, 51 and 54-56.

Please amend claims 50, 52, and 53 as follows:

50. (Twice Amended) An isolated polypeptide encoded by a DNA able to hybridize under stringent conditions to the complement of a DNA sequence encoding the carbohydrate binding domain (Trp39 to Cys155), the epidermal growth factor domain (Cys160 to Leu193); or a complement binding domain (Cys197 to Glu328) of the leukocyte homing receptor (LHR) amino acid sequence shown in FIG. 1 (SEQ ID NO:2), wherein the stringent conditions are overnight incubation at 42° C in a solution comprising 20% formamide, 5X SSC (150 mM NaCl,